Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Buy
72
CDXC Quote, Financials, Valuation and Earnings
Last price:
$7.94
Seasonality move
:
19.4%
Day range:
$7.68 - $8.00
52-week range:
$2.31 - $9.18
Dividend yield:
0%
P/E ratio:
79.56x
P/S ratio:
6.19x
P/B ratio:
13.39x
Volume:
681.6K
Avg. volume:
1.2M
1-year change:
230.83%
Market cap:
$617.3M
Revenue:
$99.6M
EPS (TTM):
$0.10
Analysts' Opinion
-
Consensus RatingChromaDex has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.82, ChromaDex has an estimated upside of 11.08% from its current price of $7.94.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $7.94.
Fair Value
-
According to the consensus of 3 analysts, ChromaDex has 11.08% upside to fair value with a price target of $8.82 per share.
CDXC vs. S&P 500
-
Over the past 5 trading days, ChromaDex has underperformed the S&P 500 by -0.59% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ChromaDex does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ChromaDex has grown year-over-year revenues for 3 quarters straight. In the most recent quarter ChromaDex reported revenues of $29.1M.
Earnings Growth
-
ChromaDex has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ChromaDex reported earnings per share of $0.09.
Enterprise value:
572.8M
EV / Invested capital:
12.43x
Price / LTM sales:
6.19x
EV / EBIT:
74.14x
EV / Revenue:
5.75x
PEG ratio (5yr expected):
--
EV / Free cash flow:
47.95x
Price / Operating cash flow:
51.62x
Enterprise value / EBITDA:
62.20x
Gross Profit (TTM):
$61.6M
Return On Assets:
14.85%
Net Income Margin (TTM):
8.59%
Return On Equity:
25.36%
Return On Invested Capital:
25.36%
Operating Margin:
24.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $72.1M | $83.6M | $99.6M | $21.2M | $29.1M | |
| Gross Profit | $42.8M | $50.8M | $61.6M | $12.9M | $18.2M | |
| Operating Income | -$18.6M | -$5.6M | $7.7M | -$168K | $7.1M | |
| EBITDA | -$16.7M | -$3.9M | $9.2M | $205K | $7.5M | |
| Diluted EPS | -$0.23 | -$0.07 | $0.10 | -- | $0.09 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $32.2M | $48.9M | $46.6M | $49.5M | $64.1M | |
| Total Assets | $38.4M | $57.8M | $54.1M | $55M | $68.3M | |
| Current Liabilities | $16.5M | $17.6M | $17.9M | $20.6M | $17.9M | |
| Total Liabilities | $21.9M | $26.1M | $25.4M | $26.5M | $22.2M | |
| Total Equity | $16.4M | $31.7M | $28.7M | $28.5M | $46.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.1M | $7.1M | $12.1M | $649K | $8.6M | |
| Cash From Investing | -$334K | -$143K | -$143K | -$21K | -$69K | |
| Cash From Financing | $7.7M | -$90K | $5.4M | -$76K | $3.7M | |
| Free Cash Flow | -$15.4M | $7M | $11.9M | $628K | $8.5M | |
CDXC
Sector
Market Cap
$617.3M
$37.4M
Price % of 52-Week High
86.49%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
230.83%
-38.36%
Beta (5-Year)
2.209
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$7.90
200-day SMA
Buy
Level
$4.56
Bollinger Bands (100)
Buy
Level
4.82 - 7.18
Chaikin Money Flow
Buy
Level
23.3M
20-day SMA
Buy
Level
$6.53
Relative Strength Index (RSI14)
Buy
Level
68.00
ADX Line
Buy
Level
30.7
Williams %R
Neutral
Level
-31.6731
50-day SMA
Buy
Level
$5.99
MACD (12, 26)
Buy
Level
0.60
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
155.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.0088)
Buy
CA Score
(Annual)
Level (1.2171)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-2.2468)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
Stock Forecast FAQ
In the current month, CDXC has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CDXC average analyst price target in the past 3 months is $8.82.
-
Where Will ChromaDex Stock Be In 1 Year?
According to analysts, the consensus estimate is that ChromaDex share price will rise to $8.82 per share over the next 12 months.
-
What Do Analysts Say About ChromaDex?
Analysts are divided on their view about ChromaDex share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ChromaDex is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is ChromaDex's Price Target?
The price target for ChromaDex over the next 1-year time period is forecast to be $8.82 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CDXC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ChromaDex is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CDXC?
You can purchase shares of ChromaDex via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ChromaDex shares.
-
What Is The ChromaDex Share Price Today?
ChromaDex was last trading at $7.94 per share. This represents the most recent stock quote for ChromaDex. Yesterday, ChromaDex closed at $7.94 per share.
-
How To Buy ChromaDex Stock Online?
In order to purchase ChromaDex stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
48
SMTC alert for Mar 18
Semtech [SMTC] is down 0.49% over the past day.
Buy
67
PLPC alert for Mar 18
Preformed Line Products [PLPC] is up 3.8% over the past day.
Buy
58
NUTX alert for Mar 18
Nutex Health [NUTX] is up 4.82% over the past day.
